Previous 10 | Next 10 |
~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to natural history of the disease ~ ~ Neurofilament Light Chain (NfL) in cerebrospinal fluid ...
LEXINGTON, Mass. and AMSTERDAM, June 20, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced the achievement of a $100 million milestone associated with the first commercial s...
CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B PR Newswire HEMGENIX ® , the first and only FDA approved gene therapy for hemophilia B, has been proven to elevate and sustain factor IX ...
2023-05-22 17:38:02 ET Summary uniQure secured FDA approval late last year and EMA approval in Q1 2023 for its AMT-061 Hemophilia B treatment. This paves the way for its commercialization in the US and EU. It also has a healthy R&D pipeline, with its Huntington’s diseas...
2023-05-20 09:19:55 ET Summary uniQure's strong financial performance and remarkable revenue growth highlight the company's continued upward trajectory, making it a promising investment opportunity. Innovative gene therapies such as HEMGENIX for hemophilia B and AMT-130 for Huntin...
2023-05-15 08:26:38 ET Dutch biotech uniQure N.V. ( NASDAQ: QURE ) added ~7% pre-market Monday after announcing an agreement to sell a portion of royalty rights expected to receive from Australian drugmaker CSL Limited ( OTCQX:CSLLY ) in relation to the gene therapy Hemgenix...
~ uniQure to receive $375 million upfront cash payment ~ ~ Under the existing agreement with CSL Behring, uniQure retains the rights to future milestones totaling up to $1.5 billion and maintains an interest in HEMGENIX ® royalties ~ ~ Capped royalty financing provi...
2023-05-09 08:42:56 ET uniQure press release ( NASDAQ: QURE ): Q1 GAAP EPS of -$1.63 misses by $0.73 . Revenue of $5.33M (+197.8% Y/Y). As of March 31, 2023, the Company had cash and cash equivalents and investment securities of $315.3 million. The Company expe...
~ Clinical update from U.S. Phase I/II trial in Huntington’s disease expected in second quarter 2023 ~ ~ Continued progress towards initiating two new Phase I/II clinical studies for AMT-260 in refractory temporal lobe epilepsy and AMT-162 in SOD1-ALS ~ LEXINGTON, Mass and ...
LEXINGTON, Mass. and AMSTERDAM, May 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 12 data presentations, including two oral presentations, will be deliver...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 2.5% to $131.38 on volume of 280,159,738 shares Maxeon Solar Technologies Ltd. (MAXN) fell 8.1% to $0.248 on volume of 217,585,873 shares Tesla Inc. (TSLA) rose 3.7% to $262.33 on volume of 159,323,492 s...
2024-07-09 15:15:03 ET Guggenheim analyst issues BUY recommendation for QURE on July 9, 2024 01:48PM ET. The previous analyst recommendation was Buy. QURE was trading at $6.278 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...